Impact of sentinel node biopsy on long-term quality of life in breast cancer patients.

Fiche publication


Date publication

novembre 2013

Auteurs

Membres identifiés du Cancéropôle Est :
Pr COUTANT Charles, Dr FRAISSE Jean


Tous les auteurs :
De Gournay E, Guyomard A, Coutant C, Boulet S, Arveux P, Causeret S, Gouy S, Padeano MM, Loustalot C, Sauzedde JM, Smail M, Combier JP, Chevillote P, Rosburger C, Bonnetain F, Fraisse J, Dabakuyo-Yonli TS

Résumé

BACKGROUND: The aim of this study was to assess long-term quality of life (QoL) over a period of 6 years in women with breast cancer (BC) who underwent sentinel lymph node biopsy (SLNB), axillary lymph node dissection (ALND), or SLNB followed by ALND. METHODS: The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ)-C30 and the EORTC-QLQ-BR-23 questionnaires were used to assess QoL before surgery, just after surgery, 6, 12 and 72 months later. The longitudinal effect of surgical modalities on QoL was assessed with a mixed model analysis of variance for repeated measurements. RESULTS: Five hundred and eighteen BC patients were initially included. The median follow-up was 6 years. During the follow-up, 61 patients died. None of the patients of the SLNB group developed lymphedema during follow-up and the relapse rate was similar in the different groups (P=0.62). Before surgery, global health status (P=0.52) and arm symptoms (BRAS) (P=0.99) QoL scores were similar whatever the surgical procedure. The BRAS score (P=0.0001) was better in the SLNB group 72 months after surgery. Moreover, during follow-up, patients treated with SLNB had lower arm symptoms scores than ALND patients and there was no difference for arm symptoms between patients treated with ALND and those treated with SLNB followed by complementary ALND. CONCLUSION: Long-term follow-up showed that SLNB was associated with less morbidity than ALND.

Référence

Br J Cancer. 2013 Nov 26;109(11):2783-91